On October 11, 2024, Aditxt, Inc., a biotech company, conducted a stakeholder update and Q&A session led by CEO Amro Albanna. The session, which was documented in a transcript filed with the SEC, addressed several key issues including NASDAQ compliance, share count post-reverse split, and the company's capital structure. Albanna clarified that dipping below a dollar does not result in immediate NASDAQ delisting, as there is a 180-day period to rectify the situation. The current outstanding number of shares is approximately 4.7 million, with capital raised through an equity line and conversions of preferred shares. Aditxt's strategy for growth includes streamlining its capital table and efficiently accessing capital through an equity line and a shelf registration. The company is also working on acquisitions and developing its Adimune™ and Pearsanta™ programs, with a focus on prostate cancer, ovarian cancer, endometriosis, infectious diseases, and women's health. Despite market challenges and the need for capital as a microcap company, Aditxt is committed to its mission and addressing stakeholder concerns through regular communication.

On October 11, 2024, Aditxt, Inc., a biotech company, conducted a stakeholder update and Q&A session led by CEO Amro Albanna. The session, which was documented in a transcript filed with the SEC, addressed several key issues including NASDAQ compliance, share count post-reverse split, and the company's capital structure. Albanna clarified that dipping below a dollar does not result in immediate NASDAQ delisting, as there is a 180-day period to rectify the situation. The current outstanding number of shares is approximately 4.7 million, with capital raised through an equity line and conversions of preferred shares. Aditxt's strategy for growth includes streamlining its capital table and efficiently accessing capital through an equity line and a shelf registration. The company is also working on acquisitions and developing its Adimune™ and Pearsanta™ programs, with a focus on prostate cancer, ovarian cancer, endometriosis, infectious diseases, and women's health. Despite market challenges and the need for capital as a microcap company, Aditxt is committed to its mission and addressing stakeholder concerns through regular communication.